Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab.
Cutaneous manifestations occur frequently in inflammatory bowel disease. The association between hidradenitis suppurativa (HS) and Crohn's disease (CD) has been reported. We present a new case supporting this association. A dramatic improvement after treatment with infliximab was achieved for both refractory fistulizing CD and axillary HS.
Martínez
F
F
Department of Gastroenterology and Hepatology, Hospital La Fe, Valencia, Spain. Fernandomarju@hotmail.com
Nos
P
P
Benlloch
S
S
Ponce
J
J
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001365:Axilla; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D017497:Hidradenitis Suppurativa / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D012006:Rectovaginal Fistula / Q000150:complications / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab